Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase I, Dose-Escalation Study Evaluating The Safety And Tolerability Of Gdc-0853 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
Conditions
Interventions
GDC-0853
Locations
10
United States
Stanford Cancer Center
Stanford, California, United States
Washington University School of Medicine
St Louis, Missouri, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Willamette Valley Cancer Ctr - 520 Country Club
Eugene, Oregon, United States
Oregon Health Sciences Uni
Portland, Oregon, United States
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc
Nashville, Tennessee, United States
Start Date
December 16, 2013
Primary Completion Date
March 8, 2022
Completion Date
March 8, 2022
Last Updated
June 21, 2022
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions